

| Questions | | Study | | | | |
|-----------|---|-------------|------------|--------------------|--------------------|--------------------|
| | | Borse et al | Wang at al | Jiang et al (2017) | Jiang et al (2016) | Jiang et al (2015) |
| 1 | Was the study objective presented in a clear, specific, and measurable manner? | 7 | 7 | 7 | 7 | 7 |
| 2 | Were the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection stated? | 4 | 4 | 4 | 4 | 4 |
| 3 | Were variable estimates used in the analysis from the best available source (i.e., randomized control trial - best, expert opinion - worst)? | 8 | 4 | 8 | 8 | 8 |
| 4 | If estimates came from a subgroup analysis, were the groups prespecified at the beginning of the study? | 0 | 1 | 0 | 0 | 1 |
| 5 | Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range of assumptions? | 9 | 9 | 9 | 9 | 9 |
| 6 | Was incremental analysis performed between alternatives for resources and costs? | 6 | 6 | 6 | 6 | 6 |
| 7 | Was the methodology for data abstraction (including the value of health states and other benefits) stated? | 2.5 | 5 | 2.5 | 5 | 5 |
| 8 | Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs that went beyond 1 year discounted (3% to 5%) and justification given for the discount rate? | 3.5 | 7 | 7 | 7 | 7 |
| 9 | Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs clearly described? | 4 | 8 | 8 | 8 | 4 |
| 10 | Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major short-term was justification given for the measures/scales used? | 6 | 6 | 6 | 6 | 6 |
| 11 | Were the health outcomes measures/scales valid and reliable? If previously tested valid and reliable measures were not available, was justification given for the measures/scales used? | 7 | 7 | 7 | 7 | 7 |
| 12 | Were the economic model (including structure), study methods and analysis, and the components of the numerator and denominator displayed in a clear, transparent manner? | 8 | 8 | 8 | 8 | 8 |
| 13 | Were the choice of economic model, main assumptions, and limitations of the study stated and justified? | 7 | 7 | 3.5 | 7 | 7 |
| 14 | Did the author(s) explicitly discuss direction and magnitude of potential biases? | 0 | 0 | 0 | 0 | 0 |
| 15 | Were the conclusions/recommendations of the study justified and based on the study results? | 8 | 8 | 8 | 8 | 8 |
| 16 | Was there a statement disclosing the source of funding for the study? | 0 | 3 | 3 | 3 | 0 |
| | Total Points | 80 | 90 | 87 | 93 | 87 |

| Questions | | Study | | | | |
|--------------|---|-------------|------------|--------------|------------|-----------------|
| | | Patel et al | Kazi et al | Soirch et al | Lala et al | Panattoni et al |
| 1 | Was the study objective presented in a clear, specific, and measurable manner? | 7 | 7 | 7 | 7 | 7 |
| 2 | Were the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection stated? | 4 | 4 | 4 | 4 | 4 |
| 3 | Were variable estimates used in the analysis from the best available source (i.e., randomized control trial - best, expert opinion - worst)? | 8 | 8 | 8 | 8 | 8 |
| 4 | If estimates came from a subgroup analysis, were the groups prespecified at the beginning of the study? | 1 | 1 | 1 | 1 | 1 |
| 5 | Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range of assumptions? | 9 | 9 | 9 | 9 | 4.5 |
| 6 | Was incremental analysis performed between alternatives for resources and costs? | 6 | 6 | 6 | 6 | 6 |
| 7 | Was the methodology for data abstraction (including the value of health states and other benefits) stated? | 5 | 5 | 2.5 | 2.5 | 2.5 |
| 8 | Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs that went beyond 1 year discounted (3% to 5%) and justification given for the discount rate? | 7 | 7 | 7 | 7 | 7 |
| 9 | Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs clearly described? | 4 | 8 | 4 | 8 | 4 |
| 10 | Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major short-term was justification given for the measures/scales used? | 6 | 6 | 3 | 6 | 6 |
| 11 | Were the health outcomes measures/scales valid and reliable? If previously tested valid and reliable measures were not available, was justification given for the measures/scales used? | 7 | 7 | 7 | 7 | 7 |
| 12 | Were the economic model (including structure), study methods and analysis, and the components of the numerator and denominator displayed in a clear, transparent manner? | 8 | 8 | 8 | 8 | 4 |
| 13 | Were the choice of economic model, main assumptions, and limitations of the study stated and justified? | 7 | 7 | 7 | 7 | 7 |
| 14 | Did the author(s) explicitly discuss direction and magnitude of potential biases? | 0 | 0 | 0 | 0 | 0 |
| 15 | Were the conclusions/recommendations of the study justified and based on the study results? | 8 | 8 | 8 | 8 | 8 |
| 16 | Was there a statement disclosing the source of funding for the study? | 3 | 3 | 3 | 3 | 3 |
| Total Points | | 90 | 94 | 84.5 | 91.5 | 79 |

| Questions | | Study | | |
|--------------|---|-------------|---------------|-----------|
| | | Reese et al | Crespin et al | Kim at al |
| 1 | Was the study objective presented in a clear, specific, and measurable manner? | 7 | 7 | 7 |
| 2 | Were the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection stated? | 4 | 4 | 4 |
| 3 | Were variable estimates used in the analysis from the best available source (i.e., randomized control trial - best, expert opinion - worst)? | 8 | 8 | 4 |
| 4 | If estimates came from a subgroup analysis, were the groups prespecified at the beginning of the study? | 1 | 1 | 1 |
| 5 | Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range of assumptions? | 9 | 9 | 9 |
| 6 | Was incremental analysis performed between alternatives for resources and costs? | 6 | 6 | 6 |
| 7 | Was the methodology for data abstraction (including the value of health states and other benefits) stated? | 2.5 | 5 | 5 |
| 8 | Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs that went beyond 1 year discounted (3% to 5%) and justification given for the discount rate? | 7 | 7 | 7 |
| 9 | Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs clearly described? | 4 | 8 | 8 |
| 10 | Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major short-term was justification given for the measures/scales used? | 3 | 3 | 6 |
| 11 | Were the health outcomes measures/scales valid and reliable? If previously tested valid and reliable measures were not available, was justification given for the measures/scales used? | 7 | 7 | 7 |
| 12 | Were the economic model (including structure), study methods and analysis, and the components of the numerator and denominator displayed in a clear, transparent manner? | 8 | 8 | 8 |
| 13 | Were the choice of economic model, main assumptions, and limitations of the study stated and justified? | 7 | 7 | 7 |
| 14 | Did the author(s) explicitly discuss direction and magnitude of potential biases? | 6 | 3 | 0 |
| 15 | Were the conclusions/recommendations of the study justified and based on the study results? | 8 | 8 | 8 |
| 16 | Was there a statement disclosing the source of funding for the study? | 0 | 3 | 0 |
| Total Points | | 87.5 | 94 | 84 |